Authors
Zhivotov V.A.1, Pavlov N.P.* 1, Jain M.2
1 Pirogov National Medical and Surgical Center, Moscow
2 University Clinic Medical Research and Educational Institute Lomonosov Moscow State University
Abstract
Parathyroid carcinoma (PC) is a rare malignant neoplasm that accounts for less than 1% of all cases of primary hyperparathyroidism (PHPT). The detection of early-stage PC is steadily increasing likely due to expanded screening of serum calcium levels. Surgical intervention is the primary and only effective treatment for primary tumor as well as for recurrent and metastatic PC. However, the optimal extent of the primary surgical procedures remains unclear. There are no specific biomarkers for PC currently. The issue of preoperative PC diagnosis remains unresolved. Topical diagnosis of these neoplasms is increasingly important, however, in practice such methods have certain limitations. In particular, ultrasound requires special training of specialists. This review presents current advances in preoperative diagnosis of PC and examines their advantages and limitations.
Keywords: рarathyroid carcinoma, primary hyperparathyroidism, laboratory examinations and diagnoses, operative surgical procedures.
References
1. Mokrysheva NG, Eremkina AK, Krupinova JA, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021; 67(4): 94-124. (In Russ.) doi: 10.14341/probl12801.
2. Dedov II, Melnichenko GA, Mokrysheva NG, et al. Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics and methods of treatment. Problems of Endocrinology. 2017; 62(6): 40-77. (In Russ.) doi: 10.14341/ probl8124-6084.
3. Mokrysheva NG, et al. Atypical parathyroid adenoma with clinically aggressive course of hyperparathyroidism: clinical case report. Endocrine Surgery. 2018; 12(1): 55-63. (In Russ.) doi: 10.14341/serg9587.
4. Mokrysheva NG, et al. Evaluation of the metabolism properties of choline kinase alpha in neoplasms of the parathyroid glands. A pilot study. Obesity and metabolism. 2019; 16(3): 94-103. (In Russ.)
5. Mokrysheva NG, Krupinova JA, Mirnaya SS. Clinical, laboratory and instrumental methods of pre-surgical diagnosis of the parathyroid glands cancer. Endocrine Surgery. 2017; 11(3): 136-145. (In Russ.) doi: 10.14341/serg20173136-145.
6. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999; 86(3): 538-544. doi: 10.1002/(sici)1097-0142(19990801)86:3%3C538::aid-cncr25%3E3.0.co;2-k.
7. Lo WM, Good ML, Nilubol N, Perrier ND, Patel DT. Tumor Size and Presence of Metastatic Disease at Diagnosis are Associated with Disease-Specific Survival in Parathyroid Carcinoma. Ann Surg Oncol. 2018; 25(9): 2535-2540. doi: 10.1245/s10434-018-6559-6.
8. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001; 2(4): 347-354. doi: 10.1007/s11864-001-0028-2.
9. Roser P, Leca BM, Coelho C, et al. Diagnosis and management of parathyroid carcinoma: a state-of-the-art review. Endocr Relat Cancer. 2023; 30(4): e220287. doi: 10.1530/ERC-22-0287.
10. van der Zwan JM, Mallone S, van Dijk B, et al. Carcinoma of endocrine organs: results of the RARECARE project. Eur J Cancer. 2012; 48(13): 1923-1931. doi: 10.1016/j.ejca.2012.01.029.
11. Sadler C, Gow KW, Beierle EA, et al. Parathyroid carcinoma in more than 1,000 patients: A population-level analysis. Surgery. 2014; 156(6): 622-1629; discussion 1629-1630. doi: 10.1016/j.surg.2014.08.069.
12. Rodrigo JP, Hernandez-Prera JC, Randolph GW, et al. Parathyroid cancer: An update. Cancer Treat Rev. 2020; 86: 102012. doi: 10.1016/j.ctrv.2020.102012.
13. Galani A, Morandi R, Dimko M, et al. Atypical parathyroid adenoma: clinical and anatomical pathologic features. World J Surg Oncol. 2021; 19(1): 19. doi: 10.1186/s12957-021-02123-7.
14. Krupinova JA. Predoperatsionnaya diagnostika raka okoloshchitovidnykh zhelez i prognozirovanie ego retsidiva s ispol’zovaniem matematicheskogo modelirovaniya i molekulyarno-geneticheskikh parametrov. [dissertation] Moskva; 2022. (In Russ).
15. Aldinger KA, Hickey RC, Ibanez ML, Samaan NA. Parathyroid carcinoma: a clinical study of seven cases of functioning and two cases of nonfunctioning parathyroid cancer. Cancer. 1982; 49(2): 388-397. doi: 10.1002/ 1097-0142(19820115)49:2%3C388::aid-cncr2820490230%3E3.0.co;2-f.
16. Villar-del-Moral J, Jiménez-García A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014; 156(5): 1132-1144. doi: 10.1016/j.surg.2014.05.014.
17. Chen Q, Kaji H, Nomura R, et al. Trial to predict malignancy of affected parathyroid glands in primary hyperparathyroidism. Endocr J. 2003; 50(5): 527-534. doi: 10.1507/endocrj.50.527.
18. Zou X, Shi L, Zhu G, et al. Fine-needle aspiration with rapid parathyroid hormone assay to identify parathyroid gland in thyroidectomy. Medicine (Baltimore). 2020; 99(16): e19840. doi: 10.1097/MD.0000000000019840.
19. Pamputis SN, Lopatnicova EN. Differential diagnosis of neck formations. Journal of New Medical Technologies. 2015; XXII(4): 74-78. (In Russ.) doi: 10.12737/17028.
20. Pamputis SN, Lopatnicova EN. Cytologic research at puncture biopsy of parathyroid glands. Tavricheskiy mediko-biologicheskiy vestnik. 2017; 20(3-2): 212-220. (In Russ.)
21. Amaral S, Rego T, Palha A, et al. Preoperative Location Of Parathyroid Adenomas In Primary Hyperparathyroidism: The Role of Cervical Doppler Ultrasound. Acta Med Port. 2023;36(4):246-253. doi:10.20344/amp.18735
22. Liu F, Zang L, Li Y, et al. Application value of contrast-enhanced ultrasound in preoperative localization of microwave ablation for primary hyperparathyroidism. J Appl Clin Med Phys. 2022; 23(12): e13802. doi: 10.1002/ acm2.13802.
23. Zafereo M, Yu J, Angelos P, et al. American Head and Neck Society Endocrine Surgery Section update on parathyroid imaging for surgical candidates with primary hyperparathyroidism. Head Neck. 2019; 41(7): 2398-2409. doi: 10.1002/hed.25781.
24. Hunter GJ, Schellingerhout D, Vu TH, Perrier ND, Hamberg LM. Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Radiology. 2012; 264(3): 789-795. doi: 10.1148/radiol.12110852.
25. Pogosian K, Karonova T, Ryzhkova D, et al. 11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary hyperparathyroidism. Quant Imaging Med Surg. 2023; 13(4): 2352-2363. doi: 10.21037/qims-22-584.
26. Slashchuk KU, Degtyarev MV, Rumyantsev PO, Troshina EA, Melnichenko GA. Imaging methods of the parathyroid glands in primary hyperparathyroidism. Literature review. Endocrine Surgery. 2020; 13(4): 153-174. (In Russ.) doi: 10.14341/serg12241.
27. Vetshev PS, et al. Current approach to the diagnosis and treatment of primary hyperparathyroidism. Khirurgiya. Zhurnal im. N.I. Pirogova. 2019; 6: 26-34. (In Russ.) doi: 10.17116/hirurgia201906126.
28. Saerens J, Velkeniers B, Keyaerts M, et al. Value of [11C]-Methionine PET/CT in Preoperative Localization of Parathyroid Adenomas. Horm Metab Res. 2021; 53(7): 444-452. doi: 10.1055/a-1475-4600.
29. Cuderman A, Senica K, Rep S, et al. 18F-Fluorocholine PET/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands. J Nucl Med. 2020; 61(4): 577-583. doi: 10.2967/jnumed.119.229914.
30. Marini F, Giusti F, Palmini G, et al. Genetics and Epigenetics of Parathyroid Carcinoma. Front Endocrinol (Lausanne). 2022; 13: 834362. doi: 10.3389/fendo.2022.834362.
31. Yart A, Gstaiger M, Wirbelauer C, et al. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol. 2005; 25(12): 5052-5060. doi: 10.1128/MCB.25.12. 5052-5060.2005.
32. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005; 25(2): 612-620. doi: 10.1128/MCB.25.2.612-620.2005.
33. Yang YJ, Han JW, Youn HD, Cho EJ. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res. 2010; 38(2): 382-390. doi: 10.1093/nar/gkp991.
34. Cardoso L, Stevenson M, Thakker RV. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Hum Mutat. 2017; 38(12): 1621-1648. doi: 10.1002/humu.23337.
35. Pandya C, Uzilov AV, Bellizzi J, et al. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight. 2017; 2(6): e92061. doi: 10.1172/jci.insight.92061.
36. Alvelos MI, Mendes M, Soares P. Molecular alterations in sporadic primary hyperparathyroidism. Genet Res Int. 2011; 2011: 275802. doi: 10.4061/ 2011/275802.
37. Svedlund J, Koskinen Edblom S, Marquez VE, et al. Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification. J Clin Endocrinol Metab. 2012; 97(7): E1307-1315. doi: 10.1210/jc.2011-3136.
38. Svedlund J, Barazeghi E, Stålberg P, et al. The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors. Endocr Relat Cancer. 2014; 21(2): 231-239. doi: 10.1530/ERC-13-0497.
39. Starker LF, Svedlund J, Udelsman R, et al. The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosomes Cancer. 2011; 50(9): 735-745. doi: 10.1002/gcc.20895.
40. Sulaiman L, Juhlin CC, Nilsson IL, et al. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism. Epigenetics. 2013; 8(6): 646-655. doi: 10.4161/epi.24823.
41. Svedlund J, Aurén M, Sundström M, et al. Aberrant WNT/β-catenin signaling in parathyroid carcinoma. Mol Cancer. 2010; 9: 294. doi: 10.1186/1476-4598-9-294.
42. Arya AK, Bhadada SK, Singh P, et al. Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas. Sci Rep. 2017; 7(1): 3123. doi: 10.1038/s41598-017-03143-8.
43. Vaira V, Elli F, Forno I, et al. The microRNA cluster C19MC is deregulated in parathyroid tumours. J Mol Endocrinol. 2012; 49(2): 115-124. doi: 10.1530/JME-11-0189.
44. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6): 904-914. doi: 10.1016/j.molcel.2011.08.018.
45. Zhang X, Hu Y, Wang M, et al. Profiling analysis of long non-coding RNA and mRNA in parathyroid carcinoma. Endocr Relat Cancer. 2019; 26(2): 163-176. doi: 10.1530/ERC-18-0480.
46. Morotti A, Forno I, Verdelli C, et al. The Oncosuppressors MEN1 and CDC73 Are Involved in lncRNA Deregulation in Human Parathyroid Tumors. J Bone Miner Res. 2020; 35(12): 2423-2431. doi: 10.1002/ jbmr.4154.
47. Bartonicek N, Maag JLV, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016; 15(1): 43. doi: 10.1186/s12943-016-0530-6.
48. Hu Y, Zhang X, Cui M, et al. Circular RNA profile of parathyroid neoplasms: analysis of co-expression networks of circular RNAs and mRNAs. RNA Biol. 2019; 16(9): 1228-1236. doi: 10.1080/15476286.2019.1622962.
49. Pogosyan KA, Karonova TL, Tsoi UA, Ryzhkova DV, Yudina OV, Grineva EN. Advantages of using PET/CT with 11C-choline compared with other methods of topical diagnosis of parathyroid adenomas. Endocrine surgery. 2023; 17(4): 79. doi: 10.14341/serg12901.
